The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-23 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
=== Diabetic foot ulcers === A 2024 meta-analysis reported that the growth factors present in PRP are vital in the healing of diabetic foot ulcers; specifically in their closure. The treatments were reported to significantly increase the healing rate in comparison to conventional treatments.
In 1944, Jones became the first Black-American to become a member of the American Society of Refrigeration Engineers. 1953 Merit Award, Phyllis Wheatley Auxiliary (Phillis Wheatley Club of Cleveland, Ohio), "for outstanding achievements which serve as an inspiration to youth." In 1977, he was posthumously inducted into the Minnesota Inventors Hall of Fame. In 1991, the National Medal of Technology was awarded to Joseph A. Numero and Frederick M. Jones. President George Bush presented the awards posthumously to their widows at a ceremony in the White House Rose Garden. Jones was the first Black American to receive the award. In 1996, the Thermo King Model 'C' refrigeration unit, the world's first front-mount refrigeration unit for mobile trucks, was designated an International Mechanical Engineering Landmark by the American Society of Mechanical Engineers. Jones designed and built the prototype from junkyard salvage. The challenges were to build a structural frame and refrigerant tubing connections that would withstand the constant pounding of road vibrations. In 2007, Jones was inducted into the National Inventors Hall of Fame, which honored him as a "Visionary Veteran." In the March 2009 issue of Heavy Duty Truck magazine, editor Tom Berg dubbed Jones "The King of Cool", and wrote that his "technological breakthrough redefined the global marketplace, with cultural reverberations felt from the world's largest cities to its most isolated villages." In 2015, Jones' achievements were recognized by the creators of a Black heritage-themed playground located in Minneapolis.
== Early life and education == Freeman was born on June 1, 1937, in Memphis, Tennessee. He is the son of Mamie Edna (née Revere; 1912–2000), a teacher, and Morgan Porterfield Freeman (July 6, 1915 – April 27, 1961), a barber, who died of cirrhosis in 1961. He has three older siblings. Some of Morgan's great-great-grandparents were slaves who migrated from North Carolina to Mississippi. He later discovered that his white maternal great-great-grandfather had lived with and was buried beside Freeman's black great-great-grandmother in the segregated South, as the two could not legally marry at the time. A DNA test suggested that among all of his African ancestors, a little over one-quarter came from the area that stretches from present-day Senegal to Liberia and three-quarters came from the Congo-Angola region. As an infant, Freeman was sent to his paternal grandmother in Charleston, Mississippi. He moved frequently during his childhood, living in Greenwood, Mississippi, Gary, Indiana, and finally Chicago. He made his acting debut aged nine, playing the lead role in a school play. He then attended Broad Street High School, a building which serves today as Threadgill Elementary School in Greenwood. At the age of 12, he won a statewide drama competition, and while settling into school, discovered music and theater. When Freeman was 16 years old, he contracted pneumonia. Freeman graduated from high school in 1955, but turned down a partial drama scholarship from Jackson State University, opting instead to enlist in the United States Air Force.
=== Outer membrane and surface antigens === The of T. pallidum has several features that have made it historically difficult to research. These include details such as its fragility. The treponemal outer membrane (OM) proteins are key factors for the bacterium's pathogenesis, persistence, and immune evasion strategies. Treponema's reputation as a "stealth pathogen" is primarily due to this unique (OM) structure, which serves to evade immune detection. The outer membrane of Treponema pallidum contains a strikingly low concentration of transmembrane proteins, approximately 100-fold lower than other gram-negative bacteria or other spirochetes. This protects the cells from antibodies attacking it, hence they exhibit a "puzzling lack of antigenicity". The genome also revealed a bundle of 12 proteins and some putative hemolysins are potential virulence factors of T. pallidum. One protein, TprK, appears to constantly mutate to avoid immune response from its host.
Sources: en.wikipedia.org
Metribolone, also known as 17α-methyltrenbolone, as well as 17α-methyl-δ9,11-19-nortestosterone or 17α-methylestra-4,9,11-trien-17β-ol-3-one, is a synthetic estrane steroid and a 17α-alkylated derivative of nandrolone (19-nortestosterone). It is the C17α methylated derivative of trenbolone (δ9,11-19-nortestosterone) and the C9- and C11-dehydrogenated (δ9,11) analogue of normethandrone (17α-methyl-19-nortestosterone). Other close relatives and derivatives of metribolone include mibolerone (7α,17α-dimethyl-19-nortestosterone) and dimethyltrienolone (RU-2420; 7α,17α-dimethyl-δ9,11-19-nortestosterone). In addition to AAS, trimethyltrienolone (R2956; 2α,2β,17α-trimethyl-δ9,11-19-nortestosterone), a highly potent antiandrogen, has been derived from metribolone.
A person with type 1 diabetes should balance insulin delivery to manage their blood glucose level. Occasionally, insufficient insulin can result in hyperglycemia. The appropriate response is to take a correction dose of insulin to reduce the blood sugar level and to consider adjusting the insulin regimen to deliver additional insulin in the future to prevent hyperglycemia. Conversely, excessive insulin delivery may result in hypoglycemia. The appropriate response is to treat the hypoglycemia and to consider adjusting the regimen to reduce insulin in the future. Somogyi and others have claimed that if prolonged hypoglycemia is untreated, then stress due to low blood sugar can result in a high blood glucose rebound. The physiological mechanisms driving the rebound are defensive. When the blood glucose level falls below normal, the body responds by releasing the endocrine hormone glucagon as well as the stress hormones epinephrine, cortisol and growth hormone. Glucagon facilitates release of glucose from the liver that raises the blood glucose immediately; the stress hormones cause insulin resistance for several hours, sustaining the elevated blood sugar.
Defining the threshold between periodontal health and gingivitis Introducing reduced periodontium to the classification to take into account patients with loss of attachment in the absence of periodontitis and post-periodontal treatment Introduction of staging and grading system to categorise periodontitis by the severity and biological features instead of the old terms of "chronic periodontitis" and "aggressive periodontitis" Introduction of "Systemic Diseases" and Conditions Affecting the Periodontal Supporting Tissues" A new classification for peri-implant health, peri-implant mucositis and peri-implantitis.
Sources: en.wikipedia.org
Thin reticular fibers (reticulin) of reticular connective tissue form a supporting meshwork inside the node. These reticular cells also form a conduit network within the lymph node that functions as a molecular sieve, to prevent pathogens that enter the lymph node through afferent vessels re-enter the blood stream. The lymph node capsule is composed of dense irregular connective tissue with some plain collagenous fibers, and a number of membranous processes or trabeculae extend from its internal surface. The trabeculae pass inward, radiating toward the center of the node, for about one-third or one-fourth of the space between the circumference and the center of the node. In some animals they are sufficiently well-marked to divide the peripheral or cortical portion of the node into a number of compartments (nodules), but in humans this arrangement is not obvious. The larger trabeculae springing from the capsule break up into finer bands, and these interlace to form a mesh-work in the central or medullary portion of the node. These trabecular spaces formed by the interlacing trabeculae contain the proper lymph node substance or lymphoid tissue. The node pulp does not, however, completely fill the spaces, but leaves between its outer margin and the enclosing trabeculae a channel or space of uniform width throughout. This is termed the subcapsular sinus (lymph path or lymph sinus). Running across it are a number of finer trabeculae of reticular fibers, mostly covered by ramifying cells.
=== Young adult and teenage users === Worldwide, increasing numbers of young people are vaping. With access to e-cigarettes, young people's tobacco use has dropped by about 75%. Most young e-cigarette users have never smoked, but there is a substantial minority who both vape and smoke. Many young people who would not smoke are vaping. Young people who smoke tobacco or marijuana, or who drink alcohol, are much more likely to vape. Among young people who have tried vaping, most used a flavored product the first time. Vaping correlates with smoking among young people, even in those who would otherwise be unlikely to smoke. In the U.S., among young people, e-cigarette use increased rapidly in the late 2010s, peaked in 2019, and had fallen substantially by 2024 (7.8% in high school students and 3.5% in middle school students). During that period, the FDA also expanded enforcement activity against unauthorized e-cigarette products. Despite these declines, e-cigarettes remained the most commonly used tobacco product among US youth for the 11th consecutive year in 2024, while cigarette smoking reached historically low levels (1.4% current use). Compared to e-cigarettes, conventional cigarette use had fallen to 1.7% among high school students and 1.1% among middle school students, the lowest prevalence recorded by the survey, according to the 2024 NYTS. Among young people who used e-cigarettes in 2024, 26.3% reported daily use and 87.6% used flavored products, with fruit flavors being the most common.
By the mid-1980s, the term in situ was adopted in materials science, particularly in the field of heterogeneous catalysis, where a catalyst in one phase facilitates a chemical reaction in a different phase. The term later expanded beyond catalysis and is now applied across various disciplines of materials science, alongside the opposite designation ex situ. For example, in situ describes the study of a sample maintained in a steady state condition within a controlled environment, where specific parameters such as temperature or pressure are regulated. This approach allows researchers to observe materials under conditions that replicate their functional states. Examples include a sample held at a fixed temperature inside a cryostat, an electrode material operating within an electric battery, or a specimen enclosed within a sealed container to protect it from external influences. In transmission electron microscopy (TEM) and scanning transmission electron microscopy (STEM), in situ refers to the observation of materials as they are exposed to external stimuli within the microscope, under conditions that mimic their natural environments. This enables real-time observation of material behavior at the nanoscale. External stimuli in in situ TEM/STEM experiments may include mechanical loading, pressure, temperature variation, electrical biasing, radiation, and environmental exposure to gases, liquids, or magnetic fields, individually or in combination.
=== Other areas === HDMI relies on the Vendor-Specific Block structure for features such as additional color spaces. DisplayPort uses the CEA EDID extensions. Both HDMI and DisplayPort have published specification for transmitting their signal over the USB-C connector (see USB-C § Alternate Mode partner specifications).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.